within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDiseaseGord.A02BX11_Troxipide;
model Troxipide 
   extends Pharmacolibrary.Drugs.ATC.A.A02BX11;

  annotation(Documentation(
    info ="<html><body><p>Troxipide is a gastroprotective agent, developed and used for the treatment of gastritis, gastric ulcers, and other gastrointestinal disorders. It acts by protecting gastric mucosa and improving gastric microcirculation. Troxipide is approved and utilized primarily in Japan and some Asian countries.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed publication reporting detailed human pharmacokinetic (PK) parameters for troxipide was found. The following parameters are estimated based on limited secondary references, typical oral drug behavior, and product prescribing information for adult healthy individuals.</p><h4>References</h4><ol><li><p>Guo, H, et al., &amp; Zhou, C (2020). Metabolites profiling and pharmacokinetics of troxipide and its pharmacodynamics in rats with gastric ulcer. <i>Scientific reports</i> 10(1) 13619–None. DOI:<a href=&quot;https://doi.org/10.1038/s41598-020-70312-7&quot;>10.1038/s41598-020-70312-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32788674/&quot;>https://pubmed.ncbi.nlm.nih.gov/32788674</a></p></li><li><p>Gao, Y, et al., &amp; Yang, X (2015). Preparation and pharmacokinetics study on gastro-floating sustained-release tablets of troxipide. <i>Drug development and industrial pharmacy</i> 41(9) 1443–1451. DOI:<a href=&quot;https://doi.org/10.3109/03639045.2014.956113&quot;>10.3109/03639045.2014.956113</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25190152/&quot;>https://pubmed.ncbi.nlm.nih.gov/25190152</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Troxipide;
